News & Updates

Show Multimedia Only
JAK inhibitors shown safe, effective in RA patients

JAK inhibitors shown safe, effective in RA patients

11 Dec 2023
One in six CYPs in SG develop long COVID

One in six CYPs in SG develop long COVID

11 Dec 2023
Myeloma patients may benefit from mezigdomide-dexamethasone doublet

Myeloma patients may benefit from mezigdomide-dexamethasone doublet

08 Dec 2023 byAudrey Abella

In a study evaluating heavily pretreated patients with relapsed and refractory multiple myeloma (R/R MM), the combination of mezigdomide and dexamethasone showed promising preliminary efficacy, with myelosuppression and infection as primary toxicities.

Myeloma patients may benefit from mezigdomide-dexamethasone doublet

08 Dec 2023